GM-CSF has demonstrated clinical benefit in the treatment of cancer patients on the basis of their immunomodulatory properties (enhancement of monocyte-mediated and dendritic cell-mediated antibody-dependent cellular cytotoxicity and T-cell cross priming) (52, –54). The gene discussed is CSF2; the disease is cancer.